UBS Group’s Foundation Medicine, Inc. FMI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-2,313
| Closed | -$316K | – | 8580 |
|
|
2018
Q2 | $316K | Sell |
2,313
-41,658
| -95% | -$3.78M | ﹤0.01% | 4657 |
|
|
2018
Q1 | $3.46M | Buy |
43,971
+37,585
| +589% | +$2.77M | ﹤0.01% | 2649 |
|
|
2017
Q4 | $436K | Sell |
6,386
-11,470
| -64% | -$595K | ﹤0.01% | 4389 |
|
|
2017
Q3 | $718K | Buy |
17,856
+5,309
| +42% | +$205K | ﹤0.01% | 3956 |
|
|
2017
Q2 | $499K | Buy |
12,547
+1,994
| +19% | +$73K | ﹤0.01% | 4115 |
|
|
2017
Q1 | $340K | Buy |
10,553
+6,182
| +141% | +$154K | ﹤0.01% | 4300 |
|
|
2016
Q4 | $78K | Sell |
4,371
-11,126
| -72% | -$240K | ﹤0.01% | 5472 |
|
|
2016
Q3 | $362K | Sell |
15,497
-4,222
| -21% | -$95.8K | ﹤0.01% | 4137 |
|
|
2016
Q2 | $368K | Buy |
19,719
+6,067
| +44% | +$110K | ﹤0.01% | 4129 |
|
|
2016
Q1 | $249K | Buy |
13,652
+7,590
| +125% | +$122K | ﹤0.01% | 4338 |
|
|
2015
Q4 | $127K | Buy |
6,062
+2,949
| +95% | +$56.8K | ﹤0.01% | 5034 |
|
|
2015
Q3 | $57K | Buy |
3,113
+1,690
| +119% | +$42.2K | ﹤0.01% | 5723 |
|
|
2015
Q2 | $48K | Sell |
1,423
-446
| -24% | -$17.9K | ﹤0.01% | 6049 |
|
|
2015
Q1 | $90K | Sell |
1,869
-1,793
| -49% | -$81.3K | ﹤0.01% | 5510 |
|
|
2014
Q4 | $82K | Buy |
+3,662
| New | +$84.5K | ﹤0.01% | 5917 |
|
UBS Group's FMI Position: Q3 2018 in Review
UBS Group sold out of Foundation Medicine, Inc. (FMI) in Q3 2018, closing a stake of 2,313 shares — an estimated $316K sold.
UBS Group first reported a position in FMI in Q4 2014 and held it in 15 quarters. The position peaked at $3.46M in Q1 2018. 0 funds tracked by Wall St. Rank hold FMI as of Q3 2018.
- UBS Group reported no remaining Foundation Medicine, Inc. position as of Q3 2018 after selling out during the quarter.
- UBS Group sold 2,313 Foundation Medicine, Inc. shares in Q3 2018, an estimated $316K.
- UBS Group first reported a position in Foundation Medicine, Inc. in Q4 2014 and held it in 15 quarters.
- UBS Group's Foundation Medicine, Inc. position peaked at $3.46M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Foundation Medicine, Inc. as of Q3 2018.
Based on UBS Group's 13F filing for Q3 2018, filed 14 Nov 2018.